MDM2 and cancer: Interaction with the mentioned proteins might destabilise AKT1, MDM2, and PRKN signalling pathways, which control cancer cells’ survival, proliferation, invasion, apoptosis, and angiogenesis, making the combined drug’s therapeutic effect promising.